Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Autonomix Medical, Inc. ( (AMIX) ).
Autonomix Medical, Inc. announced an increase in the aggregate sales price of its common stock shares under an existing At Market Issuances Sales Agreement with Ladenburg Thalmann & Co. Inc. Initially set at $2.1 million on July 26, 2024, the sales price was raised by $1.4 million on August 25, 2025, under the company’s effective shelf registration statement.
The most recent analyst rating on (AMIX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autonomix Medical, Inc. stock, see the AMIX Stock Forecast page.
Spark’s Take on AMIX Stock
According to Spark, TipRanks’ AI Analyst, AMIX is a Underperform.
Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.
To see Spark’s full report on AMIX stock, click here.
More about Autonomix Medical, Inc.
Average Trading Volume: 1,348,429
Technical Sentiment Signal: Sell
Current Market Cap: $6.86M
See more data about AMIX stock on TipRanks’ Stock Analysis page.